The Philadelphia Chromosome: The One Cancer Story With an Unusually Clean Ending, and What NCI Says Now

The Philadelphia Chromosome: A Mutant Gene and the Quest to Cure Cancer at the Genetic Level is Jessica Wapner's history of one of oncology's clearest research success stories: the discovery of a specific chromosomal abnormality behind chronic myeloid leukemia, and the five-decade path from that discovery to a drug that transformed the disease's prognosis. The Experiment published it in 2013.

It is a science history, not a memoir. Wapner, a science journalist, builds the book around the scientists whose work connected a 1960 microscope observation to a targeted drug approved in 2001, with patient accounts appearing later in the narrative as the drug reaches clinical use rather than anchoring the book throughout.

Its central subject, the Philadelphia chromosome, was the first specific genetic abnormality ever linked directly to a human cancer, discovered by researchers Peter Nowell and David Hungerford in Philadelphia in 1960, which gives the book both its title and its organizing thread.

Because the book follows a single scientific line to its conclusion, a functioning drug, it reads with more narrative momentum than most science histories, which often end with an open question rather than a clear result. That clean arc is also worth reading carefully, since CML's trajectory is not typical of most cancers, most of which do not have a single dominant genetic driver this well understood or this directly targetable.

The book is also, in a quiet way, a history of how cancer research itself has been organized and funded in the United States over the second half of the twentieth century. Wapner follows researchers across academic institutions, pharmaceutical companies, and federal funding bodies, and the difficulty of keeping a research line alive across decades, career changes, and shifting institutional priorities is as much a subject of the book as the biology itself.

The book moves in three broad stages. It opens with the 1960 discovery itself: two Philadelphia researchers noticing an unusually short chromosome in the cells of leukemia patients, at a time when the idea that cancer had a specific genetic cause was not yet established.

The middle section covers the decades of subsequent research needed to understand what that abnormal chromosome actually did: identifying the specific genes involved, BCR and ABL1, understanding how their fusion produced an abnormal protein driving uncontrolled white blood cell production, and the long, uncertain process of translating that molecular understanding into a drug candidate capable of blocking the abnormal protein specifically, rather than harming healthy cells broadly the way older chemotherapy did.

The final section follows the drug, imatinib, through its clinical trials and 2001 approval, and describes its effect on patients whose prognosis before the drug's arrival had been measured in a small number of years. This is where the book's structure shifts briefly toward individual patient accounts, illustrating what the research translated into for people actually living with the diagnosis.

The book's strength is that it makes a genuinely technical molecular story readable without oversimplifying the science, tracing exactly how a chromosomal abnormality becomes an actionable drug target, a process most popular science writing about cancer treats as a black box.

It is also valuable as a case study in how long targeted drug development actually takes, and how uncertain it looks from the inside. Four decades separated the initial 1960 discovery from the drug's 2001 approval, and the book does not smooth over the dead ends, funding struggles, and skepticism that filled those decades. That is a useful corrective for a reader who expects a straight line from genetic discovery to available treatment. The book describes periods where the research nearly stalled for lack of funding or institutional interest, and where the eventual drug's development depended on individual researchers and companies willing to pursue a molecular target that, for years, had no proven clinical payoff. Readers who assume that a clear scientific target guarantees a fast path to treatment will find that assumption directly challenged here.

Because CML's story is unusually complete, discovery, mechanism, drug, approval, and clear clinical benefit, the book also works well as an accessible introduction to how targeted cancer therapy works in general, using one of the field's cleanest examples to explain a mechanism that applies, in less tidy form, across much of modern oncology.

The book was written in 2013, and CML treatment has continued to develop since then. At the time of writing, imatinib was the central, defining drug in the story; it remains an important option today, but it is no longer the only one, and it is not automatically the first choice for every patient.

The book's framing, understandably, treats imatinib's approval as close to an ending. In practice, treatment for CML has continued to be refined since 2013, including additional approved drugs and more detailed guidance on managing side effects, resistance, and, for some patients, the possibility of eventually stopping treatment. A reader using the book to understand current CML treatment specifically should treat it as the origin story of a drug class rather than a current treatment guide.

The book's clean narrative arc is also somewhat particular to CML. Most cancers do not have a single, well-understood genetic driver of this kind, and readers should not extrapolate from CML's relatively rapid transformation into targeted-therapy success to expect a similar timeline or a similarly dramatic single breakthrough for other cancer types, many of which involve multiple interacting genetic changes rather than one dominant fusion gene.

NCI's current patient-facing treatment information for CML describes the same underlying biology the book covers, in language worth stating directly. In CML, part of the DNA from chromosome 9 moves to chromosome 22, and this rearrangement is called the Philadelphia chromosome. It results in the bone marrow producing an abnormal protein, a tyrosine kinase, that causes too many blood stem cells to develop into white blood cells.

Where NCI's information moves past the book is treatment options. NCI lists tyrosine kinase inhibitor therapy as the primary approach across CML phases, and names several specific drugs beyond imatinib: dasatinib, nilotinib, bosutinib, and asciminib. Each blocks the same abnormal protein, but they differ in side effect profiles, resistance patterns, and which specific mutations they remain effective against, giving physicians options the book's single-drug narrative does not reflect. NCI also notes that stem cell transplant remains part of the treatment landscape for more advanced phases of the disease, used alongside or after tyrosine kinase inhibitor therapy rather than as a replacement for it in most cases.

That expansion matters practically. A patient today whose CML does not respond well to, or cannot tolerate, imatinib specifically has several additional targeted options the book's protagonists did not have in 2001, a direct continuation of the research trajectory the book describes rather than a departure from it.

There is also a monitoring dimension the book, focused on the drug's discovery and approval, does not dwell on: how treatment response in CML is actually tracked. Because the disease is defined by a specific molecular marker, response can be measured with unusual precision, through blood tests tracking the BCR::ABL1 gene's activity over time, rather than relying only on imaging or symptoms. That precision, itself a direct legacy of the discovery the book describes, is part of why some patients with a sustained, very low or undetectable level of disease can, under close specialist supervision, eventually attempt stopping treatment, something not established as a realistic possibility when the book was written.

For the fuller current picture, see chronic myeloid leukemia (CML), leukemia treatment by type, and, for the broader history this discovery sits within, The Emperor of All Maladies.

It suits a reader who wants to understand how targeted cancer therapy actually gets discovered and developed, told through one of the field's clearest and most complete examples. It is a good choice for someone recently diagnosed with CML who wants to understand the science behind their own treatment's origin, as long as they pair it with current information about their specific drug options.

It is less suited to a reader looking for a personal, emotional account of living with CML day to day, since the book is built around the science and its history rather than around any one patient's ongoing experience. And a reader hoping the book will explain most cancers' genetics, rather than this one unusually well-understood case, should know that CML's story, while real and important, is not representative of how most cancer genetics work. It also is not the source to consult for guidance on side effects, dosing, or day-to-day life on a tyrosine kinase inhibitor, since the book stops largely at the point of approval rather than following patients through years of ongoing treatment, which is where most of the practical questions a newly diagnosed CML patient actually has tend to live.

Cancer Explained is free and ad-free, and you can support this work if it helped.

• The Philadelphia Chromosome — publisher's page (The Experiment)
• NCI — Chronic Myeloid Leukemia Treatment (PDQ) Patient Version
• chronic myeloid leukemia (CML) (Cancer Explained)

This page discusses The Philadelphia Chromosome for education. It is not medical advice, and nothing here is a judgement of anyone's real medical care.